Physician profile
Eric Hansen
NPI 1912260456
$13,710.89
in general payments reported to CMS, 2019-2025
19 companies · $4,441 in 2025
The $4,441 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2021: $586 · 2022: $154 · 2023: $5,792 · 2024: $2,565 · 2025: $4,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $2,030 · Travel and Lodging: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,335.00 |
| Food and Beverage | $2,029.66 |
| Travel and Lodging | $433.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $5,251.05 | 2023-2025 | Stellaris Elite, Stellaris, Stellaris |
| Genentech USA, INC. | $4,691.65 | 2021-2025 | Vabysmo, Susvimo |
| F. Hoffmann-La Roche Ag | $2,020.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $632.50 | 2019-2025 | Eylea Hd, Eylea |
| Glaukos Corporation | $177.42 | 2021 | |
| Dompe US, INC. | $147.82 | 2021 | |
| Apellis Pharmaceuticals, INC. | $143.65 | 2023 | Syfovre |
| Astellas Pharma US INC | $126.16 | 2024-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.93 | 2021 | |
| Ani Pharmaceuticals, INC. | $114.32 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Boston Scientific Corporation | $61.93 | 2019 | |
| Allergan, INC. | $46.58 | 2021 | |
| Eyepoint US, INC. | $35.01 | 2022 | |
| Recordati_rare_diseases_inc. | $31.79 | 2021 | |
| Ocular Therapeutix, INC. | $31.23 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $21.80 | 2025 | Constellation |
| Alimera Sciences, INC. | $21.00 | 2024 | Yutiq, Iluvien |
| Abbvie INC. | $18.19 | 2025 | |
| Genentech, INC. | $13.86 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.